Skip to main content
Top
Published in: Journal of Cancer Survivorship 1/2015

01-03-2015

Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients

Authors: Janne C. Mewes, Lotte M. G. Steuten, Saskia F. A. Duijts, Hester S. A. Oldenburg, Marc van Beurden, Martijn M. Stuiver, Myra S. Hunter, Jacobien M. Kieffer, Wim H. van Harten, Neil K. Aaronson

Published in: Journal of Cancer Survivorship | Issue 1/2015

Login to get access

Abstract

Purpose

Many breast cancer patients experience (severe) menopausal symptoms after an early onset of menopause caused by cancer treatment. The aim of this study was to assess the cost-effectiveness of cognitive behavioral therapy (CBT) and physical exercise (PE), compared to a waiting list control group (WLC).

Methods

We performed a cost-effectiveness analysis from a healthcare system perspective, using a Markov model. Effectiveness data came from a recent randomized controlled trial that evaluated the efficacy of CBT and PE. Cost data were obtained from relevant Dutch sources. Outcome measures were incremental treatment costs (ITCs) per patient with a clinically relevant improvement on a measure of endocrine symptoms, the Functional Assessment of Cancer Therapy questionnaire (FACT-ES), and on a measure of hot flushes, the Hot Flush Rating Scale (HFRS), and costs per quality-adjusted life years (QALY) gained over a 5-year time period.

Results

ITCs for achieving a clinically relevant decline on the FACT-ES for one patient were €1,051 for CBT and €1,315 for PE, compared to the WLC. The corresponding value for the HFRS was €1,067 for CBT, while PE was not more effective than the WLC. Incremental cost-utility ratios were €22,502/QALY for CBT and €28,078/QALY for PE.

Conclusion

CBT is likely the most cost-effective strategy for alleviating treatment-induced menopausal symptoms in this population, followed by PE. The outcomes are sensitive to a reduction of the assumed duration of the treatment effect from 5 to 3 and 1.5 years.

Implications for Cancer Survivors

Patients can be prescribed CBT or, based on individual preferences, PE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI. 2008;100:475–82.CrossRefPubMed Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI. 2008;100:475–82.CrossRefPubMed
2.
go back to reference Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI. 1995;87:190–97.CrossRefPubMed Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. JNCI. 1995;87:190–97.CrossRefPubMed
3.
go back to reference Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–88.CrossRefPubMed Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–88.CrossRefPubMed
4.
go back to reference Duijts SFA, Van Beurden M, Oldenburg HSA, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. JCI. 2012;30:4124–33. Duijts SFA, Van Beurden M, Oldenburg HSA, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. JCI. 2012;30:4124–33.
5.
7.
go back to reference Herrmann C, Cerny T, Savidan A, et al. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer. 2013;13. Herrmann C, Cerny T, Savidan A, et al. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer. 2013;13.
8.
go back to reference Jefford M, Rowland J, Grunfeld E, et al. Implementing improved post-treatment care for cancer survivors in England, with reflections from Australia, Canada and the USA. Br J Cancer. 2013;108:14–20.PubMedCentralCrossRefPubMed Jefford M, Rowland J, Grunfeld E, et al. Implementing improved post-treatment care for cancer survivors in England, with reflections from Australia, Canada and the USA. Br J Cancer. 2013;108:14–20.PubMedCentralCrossRefPubMed
9.
go back to reference Hellbom M, Bergelt C, Bergenmar M, et al. Cancer rehabilitation: a Nordic and European perspective. Acta Oncol. 2011;50:179–86.CrossRefPubMed Hellbom M, Bergelt C, Bergenmar M, et al. Cancer rehabilitation: a Nordic and European perspective. Acta Oncol. 2011;50:179–86.CrossRefPubMed
10.
go back to reference Mattioli V, Montanaro R, Romito F. The Italian response to cancer survivorship research and practice: developing an evidence base for reform. J Cancer Survivorship : Res Prac. 2010;4:284–9.CrossRef Mattioli V, Montanaro R, Romito F. The Italian response to cancer survivorship research and practice: developing an evidence base for reform. J Cancer Survivorship : Res Prac. 2010;4:284–9.CrossRef
11.
go back to reference Duijts SFA, Oldenburg HSA, van Beurden M, et al. Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial. BMC Women's Health. 2009;9. Duijts SFA, Oldenburg HSA, van Beurden M, et al. Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial. BMC Women's Health. 2009;9.
12.
go back to reference Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189–99.CrossRefPubMed Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55:189–99.CrossRefPubMed
13.
go back to reference Hunter MS, Liao KLM. A psychological analysis of menopausal hot flushes. Brit J Clin Psychol. 1995;34:589–99.CrossRef Hunter MS, Liao KLM. A psychological analysis of menopausal hot flushes. Brit J Clin Psychol. 1995;34:589–99.CrossRef
14.
go back to reference Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13:309–18.PubMedCentralCrossRefPubMed Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13:309–18.PubMedCentralCrossRefPubMed
15.
go back to reference Ware Jr JE, The SCD, MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed Ware Jr JE, The SCD, MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
16.
go back to reference Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28:172–91.CrossRefPubMed Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005;28:172–91.CrossRefPubMed
17.
go back to reference Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009;16:453–7.CrossRefPubMed Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009;16:453–7.CrossRefPubMed
18.
go back to reference Nachtigall LE, Nachtigall MJ. Menopausal changes, quality of life, and hormone therapy. Clin Obstet Gynecol. 2004;47:485–88.CrossRefPubMed Nachtigall LE, Nachtigall MJ. Menopausal changes, quality of life, and hormone therapy. Clin Obstet Gynecol. 2004;47:485–88.CrossRefPubMed
19.
go back to reference Netherlands Cancer Registry managed by CCCN. Requested data Utrecht, 2012. Netherlands Cancer Registry managed by CCCN. Requested data Utrecht, 2012.
20.
go back to reference Netherlands S. Mortality statistics. The Hague: Statistics Netherlands; 2011. Netherlands S. Mortality statistics. The Hague: Statistics Netherlands; 2011.
21.
go back to reference Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11:1131–43.CrossRefPubMed Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008;11:1131–43.CrossRefPubMed
22.
go back to reference Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16:1073–81.CrossRefPubMed Lidgren M, Wilking N, Jönsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16:1073–81.CrossRefPubMed
23.
go back to reference Hakkaart-Van Roijen L, Tan SS, Bouwmans CAM. Manual for cost research: methods and standard cost prices for economic evaluations in health care. Diemen: Health Care Insurance Board, 2010 Hakkaart-Van Roijen L, Tan SS, Bouwmans CAM. Manual for cost research: methods and standard cost prices for economic evaluations in health care. Diemen: Health Care Insurance Board, 2010
24.
go back to reference Retèl VP, Joore MA, Knauer M, et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. JC. 2010;46:1382–91. Retèl VP, Joore MA, Knauer M, et al. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. JC. 2010;46:1382–91.
25.
go back to reference Raad voor de Volksgezondheid en Zorg. Zinnige en duurzame zorg. Zoetermeer, 2006. Raad voor de Volksgezondheid en Zorg. Zinnige en duurzame zorg. Zoetermeer, 2006.
26.
go back to reference Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290–308.CrossRefPubMed Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290–308.CrossRefPubMed
27.
go back to reference Gordon LG, Beesley VL, Scuffham PA. Evidence on the economic value of psychosocial interventions to alleviate anxiety and depression among cancer survivors: a systematic review. Asia Pac J Clin Oncol. 2011;7:96–105.CrossRefPubMed Gordon LG, Beesley VL, Scuffham PA. Evidence on the economic value of psychosocial interventions to alleviate anxiety and depression among cancer survivors: a systematic review. Asia Pac J Clin Oncol. 2011;7:96–105.CrossRefPubMed
28.
go back to reference Mewes JC, Steuten LMG, IJzerman MJ, et al. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012;17:1581–93.PubMedCentralCrossRefPubMed Mewes JC, Steuten LMG, IJzerman MJ, et al. Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist. 2012;17:1581–93.PubMedCentralCrossRefPubMed
Metadata
Title
Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients
Authors
Janne C. Mewes
Lotte M. G. Steuten
Saskia F. A. Duijts
Hester S. A. Oldenburg
Marc van Beurden
Martijn M. Stuiver
Myra S. Hunter
Jacobien M. Kieffer
Wim H. van Harten
Neil K. Aaronson
Publication date
01-03-2015
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 1/2015
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-014-0396-9

Other articles of this Issue 1/2015

Journal of Cancer Survivorship 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine